Marshall Wace LLP Invests $1.54 Million in Definitive Healthcare Corp. (NASDAQ:DH)

Marshall Wace LLP purchased a new stake in Definitive Healthcare Corp. (NASDAQ:DH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 281,136 shares of the company’s stock, valued at approximately $1,535,000. Marshall Wace LLP owned 0.24% of Definitive Healthcare as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of DH. Norden Group LLC purchased a new stake in shares of Definitive Healthcare in the 1st quarter worth $83,000. Susquehanna Fundamental Investments LLC purchased a new stake in Definitive Healthcare in the first quarter worth about $120,000. Canada Pension Plan Investment Board bought a new position in Definitive Healthcare during the 2nd quarter worth about $109,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Definitive Healthcare by 31.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock valued at $116,000 after purchasing an additional 5,083 shares during the period. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of Definitive Healthcare in the 2nd quarter valued at about $127,000. Institutional investors own 98.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. downgraded shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and dropped their price objective for the company from $7.00 to $5.00 in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft dropped their target price on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating on the stock in a research report on Friday, August 9th. Morgan Stanley reduced their price target on Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Robert W. Baird dropped their price objective on Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Stifel Nicolaus cut their target price on Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.81.

Definitive Healthcare Stock Performance

DH opened at $4.34 on Friday. The company has a market cap of $511.84 million, a P/E ratio of -2.48, a price-to-earnings-growth ratio of 6.49 and a beta of 1.33. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.27. The firm’s 50-day moving average price is $4.32 and its 200-day moving average price is $5.59. Definitive Healthcare Corp. has a 52-week low of $3.19 and a 52-week high of $10.62.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09. The business had revenue of $63.70 million for the quarter, compared to analyst estimates of $63.19 million. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. Definitive Healthcare’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.08 EPS. As a group, equities analysts anticipate that Definitive Healthcare Corp. will post 0.07 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.